Table 1 Patient characteristics
|  | N = 106 |
|---|---|
Age, years | 68 [60. 75] |
Female sex, n (%) | 45 (42.5) |
BMI, kg/m2 | 21.5 [19.6, 24.3] |
Chronic HD vintage, years | 7.9 [2.9, 12.3] |
Anticoagulant during HD, n (%) | 106 (100) |
 None | 0 (0) |
 Heparin | 90 (84.9) |
 LMWH | 10 (9.4) |
 Nafamostat | 6 (5.7) |
Cause of ESRD, n (%) | 106 (100) |
 Diabetic nephropathy | 34 (32.1) |
 Nephrosclerosis | 25 (23.6) |
 Glomerulonephritis | 28 (26.4) |
 Others | 19 (17.9) |
Diabetes, n (%) | 38 (35.8) |
Ischemic heart disease, n (%) | 27 (25.5) |
Cerebrovascular disease, n (%) | 18 (17.0) |
CaSR agonist use, n (%) | 61 (57.5) |
 None | 45 (42.5) |
 Cinacalcet/ Evocalcet | 55 (51.9) |
 Etelcalcetide (i.v.) | 6 (5.7) |
VDRA use, n (%) | 97 (91.5) |
 None | 9 (8.5) |
 Alfacalcidol/ Falecalcitriol | 48 (45.3) |
 Calcitriol (i.v.) | 32 (30.2) |
 Maxacalcitol (i.v.) | 17 (16.0) |
P binder use, n (%) | 90 (84.9) |
 None | 16 (15.1) |
 Ca containing | 12 (11.3) |
 Non-Ca containing | 55 (51.9) |
 Both | 23 (21.7) |
Steroid use history, n (%) | 13 (12.3) |
β blocker use, n (%) | 48, (45.3) |
Statin use, n (%) | 28 (26.4) |
Warfarin use, n (%) | 7 (6.6) |
Bisphosphonate use, n (%) | 14 (13.2) |
Fracture history, n (%) | 15 (14.2) |
Ankle-brachial index | 1.10 [1.03, 1.18] |
Alb, g/dL | 3.6 [3.4, 3.8] |
cCa, mg/dL | 9.1 [8.5, 9.4] |
P, mg/dL | 5.4 [4.5, 6.0] |
iPTH, pg/mL | 199.1 [119.0, 277.2] |
25(OH)D, ng/mL | 14.3 [11.0, 18.9] |
1, 25(OH)2D, pg/mL | 13 [8, 19] |
BAP, μg/L | 14.2 [10.8, 18.3] |
TRACP-5b, mU/dL | 559 [339, 833] |